Skip to main content
. 2026 Mar 3;11(3):106083. doi: 10.1016/j.esmoop.2026.106083

Figure 2.

Figure 2

Figure 2

Kaplan–Meier plots for INV-assessed PFS in the selpercatinib (LIBRETTO-001) and SoC(EC,RWD) 1L and ≥2L cohorts. (A) Unadjusted 1L. (B) PSM-adjusted 1L. (C) Unadjusted ≥2L. (D) PSM-adjusted ≥2L. Red line, selpercatinib; blue line, EC. 1L, first line; 2L, second line; CI, confidence interval; EC, external control; HR, hazard ratio; INV, investigator; mPFS, median PFS; NR, not reached; PFS, progression-free survival; PSM, propensity score matching; RWD, real-world data; SoC, standard of care.